Evidence map›Paper›PMID 38842566›Full record

Trial reportAnnals of hematology2024

Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial.

Heng Mei, Xiaofan Liu, Yan Li, Hu Zhou, Ying Feng, Guangxun Gao, Peng Cheng, Ruibin Huang, Linhua Yang, Jianda Hu and 16 more

Abstract readClinical Trial, Phase IIIRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Heng MeiUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1277 Jiefang Avenue, Wuhan, Hubei, China.
Xiaofan LiuInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.288 Nanjing Road Heping District, Tianjin, China.
Yan LiWest China Hospital, Sichuan University, No.37 Guoxue Alley, Wuhou District, Chengdu, Sichuan, China.
Hu ZhouAffiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Ying FengThe Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Guangxun GaoThe First Affiliated Hospital of Air Force Medical University, Xi'an, China.
Peng ChengThe First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Ruibin HuangThe First Affiliated Hospital of Nanchang University, Nanchang, China.
Linhua YangThe Second Hospital of Shanxi Medical University, Taiyuan, China.
Jianda HuFujian Medical University Union Hospital, Fuzhou, China.
Ming HouQilu Hospital, Shandong University, Jinan, China.
Yazhou YaoBaoji Central Hospital, Baoji, China.
Li LiuThe Second Affiliated Hospital of Air Force Medical University, Xi'an, China.
Yi WangShaanxi Provincial People's Hospital, Xi'an, China.
Depei WuThe First Affiliated Hospital of Soochow University, Suzhou, China.
Xuliang ShenHeping Hospital Affiliated to Changzhi Medical College, Changzhi, China.
Jie JinThe First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China.
Jianmin LuoThe Second Hospital of Hebei Medical University, Shijiazhuang, China.
Yun ZengFirst Affiliated Hospital of Kunming Medical University, Kunming, China.
Xin ZhouWuxi People's Hospital, Wuxi, China.
Ruixiang XiaThe First Affiliated Hospital of Anhui Medical University, Hefei, China.
Zhongxing JiangThe First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yuansong BaiChina-Japan Union Hospital of Jilin University, Changchun, China.
Ting NiuWest China Hospital, Sichuan University, No.37 Guoxue Alley, Wuhou District, Chengdu, Sichuan, China. tingniu@sina.com.
Renchi YangInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.288 Nanjing Road Heping District, Tianjin, China. rcyang65@163.com.
Yu HuUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1277 Jiefang Avenue, Wuhan, Hubei, China. dr_huyu@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While studies have explored the feasibility of switching between various thrombopoietin receptor agonists in treating immune thrombocytopenia (ITP), data on the switching from eltrombopag to hetrombopag remains scarce. This post-hoc analysis of a phase III hetrombopag trial aimed to assess the outcomes of ITP patients who switched from eltrombopag to hetrombopag. In the original phase III trial, patients initially randomized to the placebo group were switched to eltrombopag. Those who completed this 14-week eltrombopag were eligible to switch to a 24-week hetrombopag. Treatment response, defined as a platelet count of ≥ 50 × 10

Indexed as

BenzoatesHydrazinesPurpura, Thrombocytopenic, IdiopathicPyrazolesPyrazolonesReceptors, ThrombopoietinAdultAgedDrug SubstitutionFemaleHumansHydrazonesMaleMiddle AgedPlatelet CountTreatment OutcomeBenzoateseltrombopaghetrombopagHydrazinesHydrazonesPyrazolesPyrazolonesReceptors, ThrombopoietinEltrombopagHetrombopagImmune thrombocytopeniaSwitchingThrombopoietin receptor agonist

Identifiers

PMID38842566
PMCPMC11224074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.